S1PR1 Knockout U251 MG Cell Line

The choice depends on whether you are studying S1PR1 (sphingosine 1-phosphate receptor 1)'s role as the principal S1P receptor in glioma biology or in modeling fingolimod (FTY720) mechanism in multiple sclerosis contexts. The Knockout line is the standard tool for asking whether S1PR1 is required for these processes — S1PR1 is the most broadly expressed S1P receptor and the principal target of fingolimod (Gilenya), the first oral disease-modifying therapy for MS. Overexpression is useful for studying receptor signaling in heterologous contexts or for testing S1PR1-selective compounds. For glioma and MS research, the EDITGENE S1PR1 Knockout in U251 MG is particularly relevant — U251 MG is a widely-used glioblastoma model, and S1PR1 has been implicated in glioma cell migration, invasion, and crosstalk with tumor immune microenvironment. Rescue with wild-type or signaling-deficient S1PR1 enables structure-function studies. The knockout serves as a critical genetic specificity control for fingolimod and next-generation S1P receptor modulators (siponimod, ozanimod, ponesimod) in MS therapeutic development.

Primary applications: • Glioma migration and invasion: wound healing, Transwell migration, and 3D invasion assays in U251 MG to assess S1PR1-dependent glioma cell motility. • S1P-induced signaling: ERK, AKT, RhoA activation following S1P stimulation; cAMP measurement for Gi-coupled S1PR1 signaling characterization. • Fingolimod and S1PR modulator specificity: critical genetic control for fingolimod (FTY720), siponimod, ozanimod, ponesimod, and emerging S1PR1-selective compounds. • Receptor internalization: imaging-based analysis of agonist-induced S1PR1 internalization — fingolimod-phosphate causes prolonged S1PR1 internalization (functional antagonism), distinct from competitive antagonists. EDITGENE recommends this model for researchers investigating glioma biology, S1P signaling in cancer, multiple sclerosis drug mechanism, and S1P receptor modulator pharmacology.

Yes. S1PR1 rescue experiments are well-established in pharmacology research: • Construct design: use a codon-modified S1PR1 sequence with a small intracellular C-terminal tag (FLAG, HA). S1PR1 is a seven-transmembrane GPCR — preserve extracellular ligand-binding pocket. • Signaling-deficient rescue: Gi-coupling-deficient mutations (e.g., DRY motif) separate ligand binding from intracellular signaling functions. • Internalization-deficient rescue: cytoplasmic tail phosphorylation site mutations affect receptor internalization — relevant for distinguishing fingolimod (functional antagonist via internalization) from competitive antagonist mechanisms. • Functional readout: rescue should restore S1P-induced cAMP modulation, ERK activation, and migration/invasion phenotypes in U251 MG glioma context. U251 MG transduces efficiently with lentivirus and supports stable rescue line generation; the glioblastoma background enables glioma-relevant S1PR1 functional studies.